Halozyme Therapeutics Ownership | Who Owns Halozyme Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Halozyme Therapeutics Ownership Summary

Halozyme Therapeutics is owned by 98.37% institutional investors, 1.08% insiders, and 0.55% retail investors. Blackrock is the largest institutional shareholder, holding 13.88% of HALO shares. iShares Core S&P Mid-Cap ETF is the top mutual fund, with 3.20% of its assets in Halozyme Therapeutics shares.

HALO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Halozyme Therapeutics	98.37%	1.08%	0.55%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	17.62M	13.88%	$922.58M
Vanguard group	12.88M	10.15%	$674.47M
State street	5.81M	4.58%	$304.43M
Snyder capital management l p	4.04M	3.18%	$211.53M
Artisan partners limited partnership	3.72M	2.93%	$194.64M
Alliancebernstein	3.55M	2.80%	$185.83M
Macquarie group	3.08M	2.42%	$161.14M
Jpmorgan chase	3.07M	2.42%	$160.84M
Geode capital management	3.03M	2.39%	$158.64M
Td asset management	2.37M	1.86%	$123.88M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Snyder capital management l p	4.04M	4.74%	$211.53M
Future fund	36.30K	4.74%	$1.89M
Steamboat capital partners	177.56K	3.41%	$9.30M
2xideas	498.96K	3.26%	$26.13M
Koa wealth management	73.57K	3.26%	$3.85M
Castellan group	108.92K	2.71%	$5.70M
Harvey capital management	186.04K	2.56%	$9.74M
Pier capital	220.45K	1.72%	$11.54M
Granite investment partners	752.84K	1.63%	$39.42M
Chase investment counsel	91.34K	1.60%	$4.78M

Top Buyers

Holder	Shares	% Assets	Change
Norges bank	1.22M	0.01%	1.22M
Frontier capital management	846.23K	0.44%	602.19K
Boston trust walden	443.30K	0.17%	443.30K
Millennium management	423.19K	0.01%	291.12K
Handelsbanken fonder ab	1.11M	0.25%	284.30K

Top Sellers

Holder	Shares	% Assets	Change
Thrivent financial for lutherans	942.83K	0.10%	-772.01K
State street	5.81M	0.01%	-673.10K
Blackrock	17.62M	0.02%	-621.61K
Lazard asset management	452.56K	0.03%	-353.42K
Qube research	40.87K	0.00%	-322.47K

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	1.22M	0.01%	1.22M	$63.68M
Boston trust walden	443.30K	0.17%	443.30K	$23.21M
Corebridge financial	227.12K	0.07%	227.12K	$11.89M
Lombard odier asset management (europe)	200.00K	0.50%	200.00K	$10.47M
Nicholas investment partners, lp	152.87K	0.83%	152.87K	$8.00M

Sold Out

Holder	Change
Harbor investment advisory	-4.00
Newbridge financial services group	-10.00
Jnba financial advisors	-24.00
Nelson, van denburg & campbell wealth management group	-26.00
Continuum advisory	-28.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	510	9.68%	124,779,138	2.05%	98	1.06%	270	11.57%	165	3.77%
Jun 30, 2024	458	9.05%	122,203,811	-0.27%	96	1.03%	237	8.22%	158	11.27%
Mar 31, 2024	420	-0.24%	122,538,335	-1.36%	96	1.09%	219	2.82%	142	-0.70%
Dec 31, 2023	421	5.25%	124,225,834	2.20%	94	1.11%	213	18.33%	143	-2.05%
Sep 30, 2023	400	4.71%	121,555,932	-1.37%	92	1.05%	180	-0.55%	146	9.77%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Core S&P Mid-Cap ETF	4.07M	3.20%	7.96K
Vanguard Total Stock Mkt Idx Inv	4.02M	3.16%	-15.97K
iShares Russell 2000 ETF	3.46M	2.72%	-7.22K
Vanguard Small Cap Index	3.18M	2.50%	6.20K
Aviva Investors GlConvtAbsRet I USD Acc	2.74M	2.16%	2.74M
SPDR® S&P Biotech ETF	2.03M	1.60%	-61.74K
Vanguard Explorer Inv	1.98M	1.56%	152.32K
Vanguard Institutional Extnd Mkt Idx Tr	1.88M	1.48%	-10.32K
Vanguard Small Cap Growth Index Inv	1.75M	1.37%	-1.79K
Delaware Small Cap Core I	1.74M	1.37%	-10.77K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 15, 2024	LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sell	$4.18K
Oct 16, 2024	LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sell	$532.59K
Oct 15, 2024	LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sell	$533.29K
Oct 08, 2024	Torley Helen	PRESIDENT AND CEO	Sell	$49.12K
Oct 09, 2024	Torley Helen	PRESIDENT AND CEO	Sell	$86.10K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	8
2024 Q3	-	25
2024 Q2	-	10
2024 Q1	-	6
2023 Q4	-	6

HALO Ownership FAQ

Who Owns Halozyme Therapeutics?

Halozyme Therapeutics shareholders are primarily institutional investors at 98.37%, followed by 1.08% insiders and 0.55% retail investors. The average institutional ownership in Halozyme Therapeutics's industry, Biotech Stocks , is 47.04%, which Halozyme Therapeutics exceeds.

Who owns the most shares of Halozyme Therapeutics?

Halozyme Therapeutics’s largest shareholders are Blackrock (17.62M shares, 13.88%), Vanguard group (12.88M shares, 10.15%), and State street (5.81M shares, 4.58%). Together, they hold 28.61% of Halozyme Therapeutics’s total shares outstanding.

Does Blackrock own Halozyme Therapeutics?

Yes, BlackRock owns 13.88% of Halozyme Therapeutics, totaling 17.62M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 922.58M$. In the last quarter, BlackRock decreased its holdings by -622K shares, a -3.41% change.

Who is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested?

Snyder capital management l p is Halozyme Therapeutics’s biggest shareholder by percentage of total assets invested, with 4.74% of its assets in 4.04M Halozyme Therapeutics shares, valued at 211.53M$.

Who is the top mutual fund holder of Halozyme Therapeutics shares?

iShares Core S&P Mid-Cap ETF is the top mutual fund holder of Halozyme Therapeutics shares, with 3.20% of its total shares outstanding invested in 4.07M Halozyme Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools